Authors: Schwartz, G Johnson, TR Goetz, A Burris, H Smetzer, L Lampkin, T Sailstad, J Hohneker, JA Von Hoff, DD Rowinsky, EK

Citation: G. Schwartz et al., A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitorof thymidylate synthase, in patients with advanced solid malignancies, CLIN CANC R, 7(7), 2001, pp. 1901-1911

Authors: Schilsky, RL Bukowski, R Burris, H Hochster, H O'Rourke, M Wall, JG Mani, S Bonny, T Levin, J Hohneker, J

Citation: Rl. Schilsky et al., A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer, ANN ONCOL, 11(4), 2000, pp. 415-420

Authors: Gerrits, CJH Schellens, JHM Burris, H Eckardt, JR Planting, AST van der Burg, MEL Rodriguez, GI Loos, WJ van Beurden, V Hudson, I Von Hoff, DD Verweij, J

Citation: Cjh. Gerrits et al., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin), CLIN CANC R, 5(1), 1999, pp. 69-75

Authors: Petit, T Aylesworth, C Burris, H Ravdin, P Rodriguez, G Smith, L Peacock, N Smetzer, L Bellet, R Von Hoff, DD Rowinsky, EK

Citation: T. Petit et al., A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies, ANN ONCOL, 10(2), 1999, pp. 223-229

Authors: Burris, H

Citation: H. Burris, Weekly schedules of docetaxel, SEMIN ONCOL, 25(6), 1998, pp. 21-23